Standing genetic variation and the evolution of drug resistance in HIV
Pleuni S. Pennings

TL;DR
This study quantifies the role of pre-existing genetic mutations in HIV drug resistance development across different treatment scenarios, highlighting key factors influencing resistance evolution.
Contribution
It provides estimates of resistance from standing variation in various treatments and models key evolutionary parameters affecting resistance emergence.
Findings
Resistance from standing variation ranges from 0% to 39%.
Approximately 6% of patients starting triple therapy develop resistance from standing variation.
Effective population size and mutant fitness are crucial in resistance evolution.
Abstract
Drug resistance remains a major problem for the treatment of HIV. Resistance can occur due to mutations that were present before treatment starts or due to mutations that occur during treatment. The relative importance of these two sources is unknown. We study three different situations in which HIV drug resistance may evolve: starting triple-drug therapy, treatment with a single dose of nevirapine and interruption of treatment. For each of these three cases good data are available from literature, which allows us to estimate the probability that resistance evolves from standing genetic variation. Depending on the treatment we find probabilities of the evolution of drug resistance due to standing genetic variation between 0 and 39%. For patients who start triple-drug combination therapy, we find that drug resistance evolves from standing genetic variation in approximately 6% of the…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
